Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer

Antonio S. Brenner, Jennifer S. Thebo, Anthony J. Senagore, Hans Joachim Duepree, Terry Gramlich, Adrian Ormsby, Ian C. Lavery, Victor W. Fazio

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Metastasis is the manifestation most directly affecting survival for patients with colorectal carcinoma. Identification of high-risk markers for metastases would allow focused selection of patients for adjuvant chemotherapy. Reports of the relationship between the putative metastasis suppressor NM23 and metastasis and/or survival in colorectal cancer patients are conflicting. The purpose of this study was to separately assess expression of NM23-H1 and NM23-H2 in primary colon cancers and determine whether expression was associated with regional nodal disease and/or liver metastases. Four patient cohorts were selected on the basis of histopathological staging at primary surgery (lymph node status/liver metastasis): -/- (n = 46), +/- (n = 47), -/+ (n = 43), and +/+ (n = 46). Primary tumors were evaluated by semiquantitative immunohistochemical analysis of NM23-H1 and NM23-H2. NM23-H2 expression was not related to survival; however, there was a modest survival advantage with low expression of NM23-H1 (P = 0.027). NM23-H1 expression in the +/+ group was increased compared with the other groups (P <0.001). The -/+ group had the lowest expression of NM23-H2 (P <0.001). This analysis distinguishes two high-risk groups of colorectal cancer patients. Prior discrepancies regarding the usefulness of NM23 staining may be explained by the need to evaluate both serotypes in addition to standard histopathological analysis to identify specific "at-risk" groups.

Original languageEnglish (US)
Pages (from-to)203-208
Number of pages6
JournalThe American surgeon
Volume69
Issue number3
StatePublished - 2003
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Survival
Adjuvant Chemotherapy
Colonic Neoplasms
Patient Selection
Liver Diseases
Lymph Nodes
Staining and Labeling
Liver
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Brenner, A. S., Thebo, J. S., Senagore, A. J., Duepree, H. J., Gramlich, T., Ormsby, A., ... Fazio, V. W. (2003). Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer. The American surgeon, 69(3), 203-208.

Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer. / Brenner, Antonio S.; Thebo, Jennifer S.; Senagore, Anthony J.; Duepree, Hans Joachim; Gramlich, Terry; Ormsby, Adrian; Lavery, Ian C.; Fazio, Victor W.

In: The American surgeon, Vol. 69, No. 3, 2003, p. 203-208.

Research output: Contribution to journalArticle

Brenner, AS, Thebo, JS, Senagore, AJ, Duepree, HJ, Gramlich, T, Ormsby, A, Lavery, IC & Fazio, VW 2003, 'Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer', The American surgeon, vol. 69, no. 3, pp. 203-208.
Brenner AS, Thebo JS, Senagore AJ, Duepree HJ, Gramlich T, Ormsby A et al. Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer. The American surgeon. 2003;69(3):203-208.
Brenner, Antonio S. ; Thebo, Jennifer S. ; Senagore, Anthony J. ; Duepree, Hans Joachim ; Gramlich, Terry ; Ormsby, Adrian ; Lavery, Ian C. ; Fazio, Victor W. / Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer. In: The American surgeon. 2003 ; Vol. 69, No. 3. pp. 203-208.
@article{8cb9cf533de04b579a3b8f9532a9198e,
title = "Analysis of both NM23-H1 and NM23-H2 expression identifies {"}at-risk{"} patients with colorectal cancer",
abstract = "Metastasis is the manifestation most directly affecting survival for patients with colorectal carcinoma. Identification of high-risk markers for metastases would allow focused selection of patients for adjuvant chemotherapy. Reports of the relationship between the putative metastasis suppressor NM23 and metastasis and/or survival in colorectal cancer patients are conflicting. The purpose of this study was to separately assess expression of NM23-H1 and NM23-H2 in primary colon cancers and determine whether expression was associated with regional nodal disease and/or liver metastases. Four patient cohorts were selected on the basis of histopathological staging at primary surgery (lymph node status/liver metastasis): -/- (n = 46), +/- (n = 47), -/+ (n = 43), and +/+ (n = 46). Primary tumors were evaluated by semiquantitative immunohistochemical analysis of NM23-H1 and NM23-H2. NM23-H2 expression was not related to survival; however, there was a modest survival advantage with low expression of NM23-H1 (P = 0.027). NM23-H1 expression in the +/+ group was increased compared with the other groups (P <0.001). The -/+ group had the lowest expression of NM23-H2 (P <0.001). This analysis distinguishes two high-risk groups of colorectal cancer patients. Prior discrepancies regarding the usefulness of NM23 staining may be explained by the need to evaluate both serotypes in addition to standard histopathological analysis to identify specific {"}at-risk{"} groups.",
author = "Brenner, {Antonio S.} and Thebo, {Jennifer S.} and Senagore, {Anthony J.} and Duepree, {Hans Joachim} and Terry Gramlich and Adrian Ormsby and Lavery, {Ian C.} and Fazio, {Victor W.}",
year = "2003",
language = "English (US)",
volume = "69",
pages = "203--208",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "3",

}

TY - JOUR

T1 - Analysis of both NM23-H1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer

AU - Brenner, Antonio S.

AU - Thebo, Jennifer S.

AU - Senagore, Anthony J.

AU - Duepree, Hans Joachim

AU - Gramlich, Terry

AU - Ormsby, Adrian

AU - Lavery, Ian C.

AU - Fazio, Victor W.

PY - 2003

Y1 - 2003

N2 - Metastasis is the manifestation most directly affecting survival for patients with colorectal carcinoma. Identification of high-risk markers for metastases would allow focused selection of patients for adjuvant chemotherapy. Reports of the relationship between the putative metastasis suppressor NM23 and metastasis and/or survival in colorectal cancer patients are conflicting. The purpose of this study was to separately assess expression of NM23-H1 and NM23-H2 in primary colon cancers and determine whether expression was associated with regional nodal disease and/or liver metastases. Four patient cohorts were selected on the basis of histopathological staging at primary surgery (lymph node status/liver metastasis): -/- (n = 46), +/- (n = 47), -/+ (n = 43), and +/+ (n = 46). Primary tumors were evaluated by semiquantitative immunohistochemical analysis of NM23-H1 and NM23-H2. NM23-H2 expression was not related to survival; however, there was a modest survival advantage with low expression of NM23-H1 (P = 0.027). NM23-H1 expression in the +/+ group was increased compared with the other groups (P <0.001). The -/+ group had the lowest expression of NM23-H2 (P <0.001). This analysis distinguishes two high-risk groups of colorectal cancer patients. Prior discrepancies regarding the usefulness of NM23 staining may be explained by the need to evaluate both serotypes in addition to standard histopathological analysis to identify specific "at-risk" groups.

AB - Metastasis is the manifestation most directly affecting survival for patients with colorectal carcinoma. Identification of high-risk markers for metastases would allow focused selection of patients for adjuvant chemotherapy. Reports of the relationship between the putative metastasis suppressor NM23 and metastasis and/or survival in colorectal cancer patients are conflicting. The purpose of this study was to separately assess expression of NM23-H1 and NM23-H2 in primary colon cancers and determine whether expression was associated with regional nodal disease and/or liver metastases. Four patient cohorts were selected on the basis of histopathological staging at primary surgery (lymph node status/liver metastasis): -/- (n = 46), +/- (n = 47), -/+ (n = 43), and +/+ (n = 46). Primary tumors were evaluated by semiquantitative immunohistochemical analysis of NM23-H1 and NM23-H2. NM23-H2 expression was not related to survival; however, there was a modest survival advantage with low expression of NM23-H1 (P = 0.027). NM23-H1 expression in the +/+ group was increased compared with the other groups (P <0.001). The -/+ group had the lowest expression of NM23-H2 (P <0.001). This analysis distinguishes two high-risk groups of colorectal cancer patients. Prior discrepancies regarding the usefulness of NM23 staining may be explained by the need to evaluate both serotypes in addition to standard histopathological analysis to identify specific "at-risk" groups.

UR - http://www.scopus.com/inward/record.url?scp=0037365989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037365989&partnerID=8YFLogxK

M3 - Article

C2 - 12678475

AN - SCOPUS:0037365989

VL - 69

SP - 203

EP - 208

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 3

ER -